Search by Drug Name or NDC
NDC 60505-6272-01 Irinotecan Hydrochloride 20 mg/mL Details
Irinotecan Hydrochloride 20 mg/mL
Irinotecan Hydrochloride is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Apotex Corp.. The primary component is IRINOTECAN HYDROCHLORIDE.
MedlinePlus Drug Summary
Irinotecan is used alone or in combination with other medications to treat colon or rectal cancer (cancer that begins in the large intestine). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It works by stopping the growth of cancer cells.
Related Packages: 60505-6272-01Last Updated: 04/28/2024
MedLinePlus Full Drug Details: Irinotecan Injection
Product Information
NDC | 60505-6272 |
---|---|
Product ID | 60505-6272_3bd941f7-1566-4b52-8b1f-48b2636deff6 |
Associated GPIs | |
GCN Sequence Number | 062174 |
GCN Sequence Number Description | irinotecan HCl VIAL 100 MG/5ML INTRAVEN |
HIC3 | V3E |
HIC3 Description | ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS |
GCN | 97956 |
HICL Sequence Number | 010778 |
HICL Sequence Number Description | IRINOTECAN HCL |
Brand/Generic | Generic |
Proprietary Name | Irinotecan Hydrochloride |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Irinotecan Hydrochloride |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 20 |
Active Ingredient Units | mg/mL |
Substance Name | IRINOTECAN HYDROCHLORIDE |
Labeler Name | Apotex Corp. |
Pharmaceutical Class | Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA203380 |
Listing Certified Through | 2024-12-31 |
Package
NDC 60505-6272-01 (60505627201)
NDC Package Code | 60505-6272-1 |
---|---|
Billing NDC | 60505627201 |
Package | 1 VIAL, SINGLE-USE in 1 CARTON (60505-6272-1) / 5 mL in 1 VIAL, SINGLE-USE |
Marketing Start Date | 2023-07-01 |
NDC Exclude Flag | N |
Pricing Information | N/A |